Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic-guided Treatment in Type 2 Diabetes
NCT06851962Phase 4Completed
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liquid metformin (Aspargo Labs), dulaglutide biosimilar 14028 injection, semaglutide, empagliflozin, canagliflozin and 5 more in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by INCLIVA Biomedical Research Institute. Primary endpoint: Proportion of patients achieving HbA1c <= 7% at 24 weeks. Started May 2025; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)dulaglutide biosimilar 14028 injectionsemaglutideempagliflozincanagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06851962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851962.